Drug recall · August 18, 2021
Zyprexa Intramuscular recall
Why: cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01
- Lots / codes
Lot # 197
- Quantity
- 36,540 vials
- Company
- Eli Lilly & Company, Indianapolis, IN
- Distribution
- OH, MS, IN
- Initiated
- June 29, 2021 · Voluntary: Firm initiated
- Classified
- August 11, 2021
- Reported
- August 18, 2021
- Ended
- July 29, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Olanzapine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.